Sanjay Kaul, MD
July 26th, 2010
Questions for Sanjay Kaul about TIDE and Avandia
Sanjay Kaul, MD and Harlan M. Krumholz, MD, SM
CardioExchange’s editor-in-chief Harlan Krumholz discussed the TIDE trial on email with Sanjay Kaul, who was a member of the FDA’s advisory panel last week on Avandia. Here is a lightly edited version of their exchange. Krumholz: What is your response to the FDA announcement that it has placed TIDE on a “partial clinical hold”? Do you […]
March 3rd, 2010
Rosiglitazone: When Evidence Is Inconclusive Even After FDA Approval
Sanjay Kaul, MD
We welcome Sanjay Kaul, MD, lead author of a recent American Heart Association/American College of Cardiology science advisory about the cardiovascular risks of thiazolidinedione drugs, to answer our questions about rosiglitazone. We encourage you to ask yours. You and your coauthors call the evidence on the cardiovascular risks of rosiglitazone “inconclusive.” When you prescribe a […]
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy